Provided by Tiger Trade Technology Pte. Ltd.

Sangamo Therapeutics Inc

0.2786
+0.00351.27%
Volume:2.04M
Turnover:576.24K
Market Cap:115.34M
PE:-0.63
High:0.2950
Open:0.2825
Low:0.2700
Close:0.2751
52wk High:0.8400
52wk Low:0.2050
Shares:414.00M
Float Shares:364.00M
Volume Ratio:1.20
T/O Rate:0.56%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4400
EPS(LYR):-0.4400
ROE:-2891.84%
ROA:-83.66%
PB:-8.08
PE(LYR):-0.63

Loading ...

Sangamo Therapeutics stellt positive Phase-1/2-Studienergebnisse für Gentherapie bei Fabry-Krankheit vor

Reuters
·
Feb 04

Sangamo Therapeutics Begins Rolling BLA Submission to FDA for Fabry Disease Gene Therapy

Reuters
·
Feb 04

Sangamo says principal financial officer Prathyusha Duraibabu terminated

TIPRANKS
·
Feb 03

Sangamo names Nikunj Jain as interim CFO, principal financial officer

TIPRANKS
·
Feb 03

Sangamo prices 35.2M shares at 47.19c in underwritten offering

TIPRANKS
·
Feb 03

Sangamo Therapeutics Prices $25 Million Offering with Warrants and Share Rights

Reuters
·
Feb 03

Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering

THOMSON REUTERS
·
Feb 03

BRIEF-Sangamo Therapeutics Inc - On Feb 2, Prathyusha Duraibabu Terminated As Principal Financial Officer - SEC Filing

Reuters
·
Feb 03

Sangamo Therapeutics Inc - on Feb 2, Prathyusha Duraibabu Terminated as Principal Financial Officer - SEC Filing

THOMSON REUTERS
·
Feb 03

Sangamo Therapeutics ernennt Nikunj Jain zum Interim-Finanzchef

Reuters
·
Feb 03

Sangamo Therapeutics Begins FDA Rolling Submission for ST-920 Gene Therapy in Fabry Disease

Reuters
·
Dec 18, 2025

Sangamo Therapeutics Inc - Expects to Complete Bla Submission by Q2 2026

THOMSON REUTERS
·
Dec 18, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Bristol Myers Squibb, Cloudflare, Boeing

Reuters
·
Dec 02, 2025

BUZZ-Sangamo jumps as US FDA fast-tracks drug for chronic nerve pain

Reuters
·
Dec 02, 2025

Sangamo Therapeutics Shares up 9.3% Premarket After Co Receives U.S. FDA Fast Track Designation for Its Experimental Treatment for Chronic Nerve Pain

THOMSON REUTERS
·
Dec 02, 2025

BRIEF-Sangamo Therapeutics Receives U.S. FDA Fast Track Designation For ST-503

Reuters
·
Dec 02, 2025

Sangamo Therapeutics Inc - Expects to Dose First Phase 1/2 Stand Study Patient in the Coming Months

THOMSON REUTERS
·
Dec 02, 2025

Vera Therapeutics Appoints James R. Meyers to Board of Directors

Reuters
·
Nov 27, 2025

Sangamo announces FDA acceptance of BLA rolling submission request for ST-920

TIPRANKS
·
Nov 21, 2025

RBC Capital Remains a Hold on Sangamo Biosciences (SGMO)

TIPRANKS
·
Nov 07, 2025